503 related articles for article (PubMed ID: 10940232)
1. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
2. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
3. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation.
Qin Z; Hu D; Zhu M; Fink AL
Biochemistry; 2007 Mar; 46(11):3521-31. PubMed ID: 17315948
[TBL] [Abstract][Full Text] [Related]
6. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
[TBL] [Abstract][Full Text] [Related]
7. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
[TBL] [Abstract][Full Text] [Related]
8. The workings of the amyloid diseases.
Bellotti V; Nuvolone M; Giorgetti S; Obici L; Palladini G; Russo P; Lavatelli F; Perfetti V; Merlini G
Ann Med; 2007; 39(3):200-7. PubMed ID: 17457717
[TBL] [Abstract][Full Text] [Related]
9. The amyloid fibrils of the constant domain of immunoglobulin light chain.
Yamamoto K; Yagi H; Lee YH; Kardos J; Hagihara Y; Naiki H; Goto Y
FEBS Lett; 2010 Aug; 584(15):3348-53. PubMed ID: 20580354
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease.
Buxbaum J
Hematol Oncol Clin North Am; 1992 Apr; 6(2):323-46. PubMed ID: 1582976
[TBL] [Abstract][Full Text] [Related]
11. Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kappa1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry.
Lim A; Wally J; Walsh MT; Skinner M; Costello CE
Anal Biochem; 2001 Aug; 295(1):45-56. PubMed ID: 11476544
[TBL] [Abstract][Full Text] [Related]
12. [Amyloidosis: a model of misfolded protein disorder].
Grateau G; Verine J; Delpech M; Ries M
Med Sci (Paris); 2005; 21(6-7):627-33. PubMed ID: 15985206
[TBL] [Abstract][Full Text] [Related]
13. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease.
Kaplan B; Livneh A; Gallo G
Br J Haematol; 2007 Mar; 136(5):723-8. PubMed ID: 17223908
[TBL] [Abstract][Full Text] [Related]
14. Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation.
Bergen HR; Abraham RS; Johnson KL; Bradwell AR; Naylor S
Biomed Chromatogr; 2004 Apr; 18(3):191-201. PubMed ID: 15103706
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
Picken MM
Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
[TBL] [Abstract][Full Text] [Related]
16. Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.
Olsen KE; Sletten K; Westermark P
Biochem Biophys Res Commun; 1998 Oct; 251(2):642-7. PubMed ID: 9792827
[TBL] [Abstract][Full Text] [Related]
17. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
18. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
19. [Immunoglobulin amyloidosis].
Hermine O; Bourquelot P; Buzyn A; Aucouturier P
Rev Prat; 1997 Oct; 47(16):1787-91. PubMed ID: 9453204
[TBL] [Abstract][Full Text] [Related]
20. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
